Clearmind Medicine (CMND) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$2.0M

Net income growth (year over year)

−161.20%

Net margin

—

Return on equity

−114.61%

EPS (trailing twelve months)

−$374.93

Book value per share

$90.21

P/E (trailing twelve months)

—

Price to book

0.28

Debt to assets

20.88%

Payout ratio

—

Dividend yield

—

Company profile

Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.

• How do I buy stock in Clearmind Medicine (CMND)?

  CMND trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.